Study S002260

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in Type 2 Diabetes Mellitus (T2DM)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT02981069
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 90
Start: 2017-12-15
Primary completion: 2022-07-14
Lead sponsor: The University of Texas Health Science Center at San Antonio
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Dapagliflozin; DRUG:Exenatide; DRUG:Placebo
Results posted: TRUE

Registered primary outcomes

Change in Endogenous Glucose Production (EGP) After Acute Exposure to a Single Dose and Again After 16 Weeks of Treatment [ACUTE [after a single dose of each study drug or placebo]]
Change in Endogenous Glucose Production (EGP) After 16 Weeks of Treatment With Each Study Drug. [16 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.